The Centers for Disease Control and Prevention (CDC) has issued a notice regarding increased influenza A(H3N2) activity and its clinical implications, a summary of influenza antiviral drug treatment recommendations, an update about approved treatment drugs and supply for the 2017-2018 season, and background information for patients about influenza treatment. Recommendations include:
- CDC recommends antiviral medications for the treatment of influenza as an important adjunct to annual influenza vaccination.
- All hospitalized, severely ill, and high-risk patients with suspected confirmed influenza should be treated with antivirals.
- Antiviral treatment should be started as soon as possible after illness onset and should not be delayed even for a few hours to wait for the results of testing.
- The most accurate influenza tests are molecular assays.
- Neuraminidase inhibitors can benefit other individuals with influenza. Three prescription neuraminidase inhibitor antiviral medications are recommended for use the US during the 2017-2018 season: iseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab).
- Additional considerations for clinicians include bacterial infections and adverse events with antiviral use.
Centers for Disease Control and Prevention. Seasonal influenza A(H3N2) activity and antiviral treatment of patients with influenza. December 27, 2017. https://emergency.cdc.gov/han/han00409.asp. Accessed December 30, 2017.
The CDC announced that the predominant circulating influenza virus this year is influenza A(H3N2). In general vaccine effectiveness in the past has been lower against A(H3N2) viruses than against influenza A(H1N1), and in the past the vaccine was only approximately 30% effective in protecting against A(H3N2). This means that the use of antiviral therapy for high-risk patients may be particularly important during this year’s flu outbreak. High risk individuals include:
- Adults aged 65 years and older.
- Persons with chronic pulmonary (including asthma), cardiovascular (except hypertension alone), renal, hepatic, hematological (including sickle cell disease), and metabolic disorders (including diabetes mellitus), or neurologic and neurodevelopment conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy).
This Week's Must Reads
HRRP & Patient Mortality in HF, AMI & Pneumonia, JAMA; 2018 Dec 25; Wadhera, et al
Hypertensive Diseases of Pregnancy & Risk of HF, Mayo Clin Proc; ePub 2018 Dec 19; Nizamuddin, et al
Clopidogrel + Aspirin Can Reduce Recurrent Stroke, BMJ; ePub 2018 Dec 18; Hao, Tampi, et al
Second-Line ADMs & CV Events in T2D, JAMA Netw Open; ePub 2018 Dec 21; O’Brien, et al
Health Care Utilization of a Dementia Care Program, JAMA Intern Med; ePub 2018 Dec 21; Jennings, et al
Must Reads in Infectious Diseases
Hospitalization Trends for Drug-Use Associated IE, Ann Intern Med; ePub 2018 Dec 4; Schranz, et al
Healthcare-Associated Infections in US Hospitals, N Engl J Med; 2018 Nov 1; Magill, O’Leary, et al
Gaps in HIV PrEP by Race and Ethnicity, MMWR; 2018 Oct 19; Huang, Zhu, et al
Trends in HPV-Associated Cancers in the US, MMWR; 2018 Aug 24; Van Dyne, Henley, et al
HIV Viral Suppression Trends in the US, Ann Intern Med; ePub 2018 Aug 21; Nance, et al